Enhanced green fluorescent protein (EGFP) is a novel marker gene product, which is readily detectable using techniques of fluorescence microscopy, flow cytometry, or macroscopic imaging. In the present studies, we have examined the immunogenicity of EGFP in murine models. A stable transfectant of the transplantable CMS4 sarcoma of BALB/c origin expressing EGFP, CMS4-EGFP-Zeo, was generated. Splenocytes harvested from mice immunized with a recombinant adenovirus expressing EGFP (Ad-EGFP) were restimulated in vitro with CMS4-EGFP-Zeo. Effector lymphocytes displayed strong cytotoxicity against CMS4-EGFPZeo, but not against mock-transfected CMS4-Zeo tumor
Genetic immunization represents a novel strategy for the experimental development of antigen-specific vaccines against infectious diseases and cancer. 1, 2 Several nonviral as well as viral gene transfer systems are currently being investigated and compared with other vaccine vehicles consisting of synthetic peptides or recombinant proteins. 2, 3 The use of ␤-galactosidase, chicken ovalbumin, hen egg lysozyme, and viral antigens such as influenza hemaglutinin or ECMV glycoprotein as model antigens in murine studies has greatly improved our understanding of cellular immune responses at the molecular level. The identification of peptide epitopes derived from these antigens which bind to MHC class I and MHC class II molecules and are recognized by CD8 + and CD4 + T cells, respectively, allows for the assessment of the efficacy of various vaccine strategies in stimulating antigen-specific cellular immunity in these experimental models. This knowledge has also been applied in the field of tumor immunology. For example, it has been shown that immunization of mice against the model antigen ␤-galactosidase or chicken ovalbumin using various gene delivery systems can protect against a subsequent chal-cells. A number of candidate H2-K d -binding peptides derived from the EGFP protein were chosen according to an epitope prediction program and synthesized. These peptides were tested for their ability to bind to H2-K d molecules and stimulate IFN␥-production by splenocytes harvested from Ad-EGFP-immunized mice. Using this methodology, the peptide, HYLSTQSAL (corresponding to EGFP [200] [201] [202] [203] [204] [205] [206] [207] [208] lenge with tumor cells stably transduced with the same model antigen. [2] [3] [4] [5] [6] [7] [8] [9] These experimental systems are currently employed for the comparison and continued development of effective vaccine strategies particularly as a therapy of established tumors.
Recently, cDNA encoding a green fluorescent protein (GFP) was isolated from the jellyfish, Aequorea victoria. GFP absorbs blue light (maximum 395 nm) and emits green light (maximum 509 nm) due to its particular protein structure. 10 The intrinsic fluorescence of GFP does not require any additional proteins, substrates, or cofactors. Moreover, GFP fluorescence is stable, species-independent, and can be monitored noninvasively using techniques of fluorescence microscopy, flow cytometry, and macroscopic imaging. [10] [11] [12] [13] For these reasons, GFP is now routinely used as a reporter molecule to monitor gene expression.
14 Enhanced green fluorescent protein (EGFP) is a red shifted variant, which fluoresces much more intensely than wild-type GFP. Importantly, EGFP can readily be detected by flow cytometry because it efficiently absorbs light at 488 nm emitted by the FACS laser. 15 One potential problem with the use of EGFP as marker is that it may be immunogenic, thus limiting its use in clinical studies. However, if EGFP is immunogenic it could be useful as a model antigen for development of tumor-specific vaccines. To this end, the immunogenic BALB/c sarcoma CMS4 was stably transduced with 16 In subsequent experiments, the cytotoxic T cell response against EGFP was studied in vitro. BALB/c mice were immunized by a single intraperitoneal injection of 5 × 10 8 p.f.u. of Ad-EGFP, a recombinant adenovirus encoding EGFP. A control group of mice received the same amount of Ad-⌿5, a recombinant adenovirus without insert. Two or three weeks later, splenocytes were harvested from both groups of immunized mice, restimulated in vitro with irradiated CMS4-EGFP-Zeo for 5 days, and assessed for their cytotoxic activity against CMS4-EGFP-Zeo and CMS4-Zeo in standard chromium release assays ( Figure 2 ). The results indicated that the effectors obtained from Ad-EGFP-immunized mice were cytotoxic to CMS4-EGFP-Zeo, but not the control CMS4-Zeo cell line, and that effectors obtained from control Ad-⌿-immunized mice displayed no cytotoxic reactivity against either target cell line tested. These experiments demonstrated the existence of cytotoxic effectors, presumably CTL, which recognize EGFP endogenously expressed in CMS4 sarcoma cells of BALB/c origin. A similar CTL response was observed in BALB/c mice after rejection of BM185 expressing EGFP. 16 In order to utilize EGFP as a potential model tumor antigen, a peptide epitope recognized by EGFP-specific CTL was identified. The computer program developed by Parker et al 17 was consulted for selection of potential MHC class I-binding epitopes. The 10 EGFP-encoded peptides with the highest predicted binding affinities for H2-K d molecules were selected for synthesis. The algorithm did not yield any peptides with significant binding affinities for H-2D d molecules. The selected peptides were first evaluated for their ability to stabilize the expression of H2-K d molecules on the surface of the TAPdeficient cell line T2, 18 stably transfected to express H-2K d molecules. Only empty MHC class I molecules arrive on the surface of T2 cells due to lack of functional TAP. These are unstable at 37°C and rapidly disintegrate. However, MHC class I molecules are considerably more stable at room temperature and can be loaded with peptides externally. Peptide-MHC class I complexes remain stable when T2 cells are shifted to 37°C. The stabilization of MHC class I expression on the surface of T2 cells under these conditions therefore indirectly reflects the binding affinity of a given peptide to MHC class I molecules. 19 As shown in Figure 3 , two of the 10 candidate peptides, KFICTTGKL (EGFP 46-54 ) and HYLSTQSAL (EGFP 200-208 ), were able to stabilize expression of H2-K d on T2-Kd cells. The candidate EGFP-derived peptides were analyzed for recognition by cytotoxic effectors induced from Ad-EGFP-immunized BALB/c mice. Using the ELISPOT technique, each peptide was evaluated for its ability to stimulate the production of IFN␥ among splenocytes harvested from Ad-EGFP-immunized mice. As indicated in Figure 4 , only the EGFP-derived peptide HYLSTQSAL (EGFP [200] [201] [202] [203] [204] [205] [206] [207] [208] ), was recognized by these effectors. This peptide also displayed the highest binding affinity to H2-K d molecules (see Figure 3) . The reactivity to HYLSTQSAL (EGFP [200] [201] [202] [203] [204] [205] [206] [207] [208] ) was strong compared with that observed with other CTL-defined peptides derived from ␤-galactosidase or ovalbumin (data not shown). To confirm that EGFP-specific CTL recognize the EGFP 200-208 epitope, EGFP-specific CTL generated by in vitro restimulation of splenocytes harvested from Ad-EGFP-immunized mice with irradiated CMS4-EGFP-Zeo were tested for cytotoxic reactivity against CMS4 cells pulsed with either EGFP [46] [47] [48] [49] [50] [51] [52] [53] [54] Figure 2 . In vitrorestimulated lymphocytes were tested for their cytolytic reactivity against CMS4 cells pulsed with 1 g/ml of the EGFP-derived peptides KFICTTGKL [46] [47] [48] [49] [50] [51] [52] [53] [54] and HYLSTQSAL [200] [201] [202] [203] [204] [205] [206] [207] [208] in standard 4-h 51 Cr release assays, as described in Figure 2 . Data represent one experiment of three.
) and HYLSTQSAL (EGFP 200-208 ). These peptides were synthesized by standard F-moc chemistry and purified by HPLC by the Peptide Synthesis facility of the University of Pittsburgh Cancer Institute (shared resource). The binding-activity of candidate peptides to H2-K d molecules was determined by their ability to stabilize the expression of K d on the TAP-deficient T2 cells expressing H2-K d (T2-K d cells). T2-K d cells were incubated at RT for 12-18 h to increase surface
purified recombinant protein is available, allowing for detection of EGFP-specific T helper cell responses as well as antibodies. The utility of EGFP as a model antigen can best be demonstrated in the development of dendritic cell-based genetic immunization. Dendritic cells are bone marrow-derived leukocytes, which are critical antigen presenting cells for the induction of cellular immunity. 20, 21 Dendritic cells can be generated in culture, transduced with antigen ex vivo, and applied as a vaccine. Transduction efficiency and dendritic cell phenotype and function are key parameters for vaccine efficacy. Using EGFP as a model antigen, transduction efficiency and dendritic cell phenotype can easily be monitored using flow cytometry for a given vaccine strategy. 22, 23 Using the EGFP 200-208 peptide epitope and recombinant EGFP, we have been able to assess simultaneously the induction of CTL and antibody responses in BALB/c mice following genetic immunization with recombinant adenovirus either injected directly or with cultured dendritic cells (data not shown). Novel gene delivery systems for antigen expression in dendritic cells both in vitro or directly in vivo are currently being developed for vaccine purposes. Our results will allow the use of EGFP not only as a marker for DC gene transfer but as a model tumor antigen.
These results are also of considerable value for the continued development of gene delivery systems able to mediate long-term transgene expression in vivo. This is a requirement for many applications of gene therapy such as gene correction or replacement. A major obstacle of current research is the induction of immune responses to transgene products using available gene transfer technologies, severely limiting the duration of gene expression in vivo. An ideally suited strategy for long-term gene transfer using EGFP as a marker could involve induction of tolerance to the EGFP 200-208 peptide without detectable CTL or antibody responses.
